Record Revenue Growth
OrthoPediatrics achieved record revenue with global growth of 16% in Q2 2025, driven by market share gains across all business segments.
Scoliosis Business Expansion
The Scoliosis segment demonstrated a 35% growth, driven by increased sales of RESPONSE, ApiFix, and 7D technologies.
OPSB Expansion Success
The OPSB segment experienced over 20% growth and expanded into two large markets, New York City and California, as well as internationally in Ireland.
FDA Approvals and Product Launches
Received FDA approval for sterile products, and the first surgical case using the 3P Pediatric Plating Platform Hip system was completed.
Improved EBITDA
Adjusted EBITDA improved by 50%, increasing from $2.6 million in Q2 2024 to $4.1 million in Q2 2025.